

**KURZPROTOKOLL**  
**CCTL019A2205B**

|                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|--------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Öffentlicher Titel</b>                        | Langzeit-Follow-up-Studie nach Behandlung mit CAR T-Zellen                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Wissenschaftl. Titel</b>                      | Long Term Follow-Up of Patients Exposed to Lentiviral-Based CD19 directed CAR T-Cell Therapy                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Kurztitel</b>                                 | CCTL019A2205B                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Studienart</b>                                | multizentrisch, prospektiv, Therapiestudie, offen/unverblindet, einarmig, Pharma-Studie                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Studienphase</b>                              | Phase II/III                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Erkrankung</b>                                | Blut: Akute lymphatische Leukämie (ALL): sonstige Studien für akute Leukämien<br>Kinder: Leukämien und Lymphome: Rezidiert/refraktär                                                                                                                                                                                                                                                                                                                                                      |
| <b>Einschlusskriterien</b>                       | <ul style="list-style-type: none"><li>- All patients who have received CD19 CAR T-cell therapy, murine (CTL019) and/or humanized (CTL119) CD19-directed CAR T cell treatment, manufactured by Novartis or University of Pennsylvania (Penn) and participated in a Novartis or Penn sponsored treatment protocol or a Novartis managed access program</li><li>- Patients who have provided informed consent for the long term follow up study prior to their study participation</li></ul> |
| <b>Ausschlusskriterien</b>                       | <ul style="list-style-type: none"><li>- There are no specific exclusion criteria for this study</li></ul>                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Alter</b>                                     | 2 Jahre und älter                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Molekularer Marker</b>                        | CD19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Prüfzentren</b>                               | <b>Kinder- und Jugendmedizin (Aktiv)</b><br>Schwerpunkt Stammzelltransplantation, Immunologie und Intensivmedizin<br>Theodor-Stern-Kai 7<br>60590 Frankfurt am Main<br>Prof. Dr. med. Peter Bader<br>Tel: 069 6301-7542<br>Fax: 069 6301-4202<br><a href="mailto:peter.bader@unimedizin-ffm.de">peter.bader@unimedizin-ffm.de</a>                                                                                                                                                         |
| <b>Sponsor</b>                                   | Novartis Pharma                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Registrierung in anderen Studienregistern</b> | ClinicalTrials.gov NCT02445222 (primäres Register)<br>EudraCT 2014-001673-14                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Links</b>                                     | <a href="#">zu den Ein- und Ausschlusskriterien</a>                                                                                                                                                                                                                                                                                                                                                                                                                                       |